LGALS3 and COVID-19: In the context of COVID-19, Gal-3 promotes the activation of fibroblasts and macrophages, leading to lung fibrosis, a common consequence of the prolonged inflammatory response in severe cases, contributing to the deterioration of lung function and poor clinical outcomes (15).